Allergan, Inc.

Apollo Endosurgery, Inc.

Allergan Industrie, Sas

Dimitrios Stroumpoulis

Christopher S Mudd

Ahmet Tezel

Nicholas J Manesis

Futian Liu

Alexei Goraltchouk

Zachary Dominguez

Justin J Schwab

Ethan W Franklin

Bastien Mandaroux

Edwin Kayda

Dustin Leslie

David J Schuessler

Joseph S Raven

Thomas E Powell

Nick Manesis

Karina Heredia Guillen

Nikhil S Trilokekar

Kaustubh S Chitre

Blanca Guillen

James A Harders

Skin can be treated by piercing skin with a plurality of needles of an injection device and ejecting a dose of fluid therethrough. The device can include a housing, a plunger disposed in the housing, a cartridge disposed in the housing, and one or more dosing chambers. The plurality of needles can be coupled to the housing and be in fluid communication with the cartridge. Advancement of the plunger can cause a dose of fluid to be ejected from the plurality of needles.

Devices for injection and dosing

Injection devices are provided which include a handpiece capable of housing a cartridge containing an injectable composition, and a head coupled to the handpiece and housing a plurality of retractable needles and a dosing mechanism. Methods of treating skin surfaces are also provided.

A syringe is disclosed. The syringe may include a syringe body with a fluid chamber, the syringe body having a distal end and a proximal end, with an extrusion opening at the proximal end; a dividing wall disposed within the fluid chamber, defining a first fluid chamber and a second fluid chamber, the first fluid chamber and the second fluid chamber in communication with the extrusion opening; a first plunger disposed in a distal end of the first chamber, the first plunger including a first locking mechanism configured to prevent the first plunger from sliding away from the proximal end of the syringe body, when the first plunger is in a first initial position and the second plunger is being depressed; and a second plunger disposed in a distal end of the second chamber, the second plunger including a second locking mechanism configured to prevent the second plunger from sliding away from the proximal end of the syringe body when the second plunger is in a second initial position and the first plunger is being depressed.

Syringe

The present specification discloses porous materials, methods of forming such porous materials, materials and devices comprising such porous materials, and methods of making such materials and devices.

Porous materials, methods of making and uses

The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.

An implantable injection port facilitates filling and/or draining an inflatable portion of a gastric band. In an embodiment, the port comprises a movable cap that causes anchor wires to extend from anchor devices in order to implant the injection port in the tissue of a patient. In another embodiment, the port comprises a handle that rotates to implant curved anchors into the tissue of a patient. In yet another embodiment, a cap is configured to move towards a base of the port in order to cause the curved anchors to rotate into the tissue of a patient. The cap may also rotate with respect to the base in order to lock the cap and the anchors in position. Further, surfaces of the injection port may be textured to increase adhesiveness to the patient's tissue during installation and to facilitate simpler installation.

Implantable injection port

Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications.

Polysaccharide gel formulation having increased longevity

An implantable device comprises a reservoir that contains a fluid for filling an inflatable portion of a gastric band. A device is coupled to the reservoir and includes stored potential energy having a first state and a second state. The first state represents a higher level of potential energy and the second state represents a lower level of potential energy. The implantable device further comprises a filling valve coupled between the reservoir and the gastric band, and the filling valve is configured to be opened in response to a first telemetric signal. The stored potential energy decreases from the first state to the second state when the filling valve is open, and a filling amount of the fluid moves from the reservoir to the gastric band when the stored potential energy decreases from the first state to the second state.

Remotely adjustable gastric banding system

Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.

Polysaccharide gel formulation having multi-stage bioactive agent delivery

The present invention generally relates to novel biocompatible crosslinked polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. In one aspect of the invention, a novel polyethylene glycol crosslinking agent is described for crosslinking hyaluronic acid. In another aspect of the invention, novel crosslinking agents comprising more than two functional groups are described. These multifunctional crosslinking agents can be used on their own to crosslink hyaluronic acid, or they may be combined with bifunctional crosslinking agents in varying ratios to make hyaluronic acid of tunable mechanical strength and hardness. The present invention also discloses novel hyaluronic acid compositions that have been coated with polyethylene glycol and methods of their use.

Growing community of inventors

Goleta, CA, United States of America

Dimitrios Stroumpoulis